85 related articles for article (PubMed ID: 19440217)
1. Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.
Cho BS; Lee S; Kim YJ; Chung NG; Eom KS; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Kim CC
Leukemia; 2009 Oct; 23(10):1763-70. PubMed ID: 19440217
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience.
Anderlini P; Saliba R; Acholonu S; Giralt SA; Andersson B; Ueno NT; Hosing C; Khouri IF; Couriel D; de Lima M; Qazilbash MH; Pro B; Romaguera J; Fayad L; Hagemeister F; Younes A; Munsell MF; Champlin RE
Haematologica; 2008 Feb; 93(2):257-64. PubMed ID: 18223284
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia.
Sanders JE; Im HJ; Hoffmeister PA; Gooley TA; Woolfrey AE; Carpenter PA; Andrews RG; Bryant EM; Appelbaum FR
Blood; 2005 May; 105(9):3749-56. PubMed ID: 15637143
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic Hematopoietic Stem Cell Transplantation with Myeloablative Conditioning Is Associated with Favorable Outcomes in Mixed Phenotype Acute Leukemia.
Getta BM; Roshal M; Zheng J; Park JH; Stein EM; Levine R; Papadopoulos EB; Jakubowski AA; Kernan NA; Steinherz P; O'Reilly RJ; Perales MA; Giralt SA; Tallman MS; Shaffer BC
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1879-1886. PubMed ID: 28694182
[TBL] [Abstract][Full Text] [Related]
5. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.
Gribben JG; Zahrieh D; Stephans K; Bartlett-Pandite L; Alyea EP; Fisher DC; Freedman AS; Mauch P; Schlossman R; Sequist LV; Soiffer RJ; Marshall B; Neuberg D; Ritz J; Nadler LM
Blood; 2005 Dec; 106(13):4389-96. PubMed ID: 16131571
[TBL] [Abstract][Full Text] [Related]
6. Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation.
Mohty M; Labopin M; Volin L; Gratwohl A; Socié G; Esteve J; Tabrizi R; Nagler A; Rocha V;
Blood; 2010 Nov; 116(22):4439-43. PubMed ID: 20716774
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.
Yoon JH; Lee S
Korean J Intern Med; 2024 Jan; 39(1):34-56. PubMed ID: 38225824
[TBL] [Abstract][Full Text] [Related]
8. Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score-matched cohort analysis.
Yoon JH; Kwag D; Lee JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Wook Lee J; Lee S
Ther Adv Hematol; 2023; 14():20406207231154713. PubMed ID: 36895914
[TBL] [Abstract][Full Text] [Related]
9. Conditioning Regimens for Frail Patients with Acute Leukemia Undergoing Allogeneic Stem Cell Transplant: How to Strike Gently.
Saraceni F; Scortechini I; Fiorentini A; Dubbini MV; Mancini G; Federici I; Colaneri FR; Lotito AF; Guerzoni S; Puglisi B; Olivieri A
Clin Hematol Int; 2021 Dec; 3(4):153-160. PubMed ID: 34938987
[TBL] [Abstract][Full Text] [Related]
10. A risk score system for stratifying the risk of relapse in B cell acute lymphocytic leukemia patients after allogenic stem cell transplantation.
Cao LQ; Zhou Y; Liu YR; Xu LP; Zhang XH; Wang Y; Chen H; Chen YH; Wang FR; Han W; Sun YQ; Yan CH; Tang FF; Mo XD; Liu KY; Fan QZ; Chang YJ; Huang XJ
Chin Med J (Engl); 2021 Mar; 134(10):1199-1208. PubMed ID: 33734137
[TBL] [Abstract][Full Text] [Related]
11. Comparison of reduced-intensity conditioning regimens in patients with acute lymphoblastic leukemia >45 years undergoing allogeneic stem cell transplantation-a retrospective study by the Acute Leukemia Working Party of EBMT.
Peric Z; Labopin M; Peczynski C; Polge E; Cornelissen J; Carpenter B; Potter M; Malladi R; Byrne J; Schouten H; Fegueux N; Socié G; Rovira M; Kuball J; Gilleece M; Giebel S; Nagler A; Mohty M
Bone Marrow Transplant; 2020 Aug; 55(8):1560-1569. PubMed ID: 32361712
[TBL] [Abstract][Full Text] [Related]
12. Experience of blinatumomab salvage for patients with acute lymphoblastic leukemia presenting with isolated extramedullary relapse after previous allogeneic hematopoietic cell transplantation.
Yoon SY; Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S
Bone Marrow Transplant; 2020 Jul; 55(7):1469-1472. PubMed ID: 31591448
[No Abstract] [Full Text] [Related]
13. Perspectives on the Use of a Medium-Dose Etoposide, Cyclophosphamide, and Total Body Irradiation Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation: The Japanese Experience from 1993 to Present.
Imamura M; Shigematsu A
J Clin Med; 2019 Apr; 8(5):. PubMed ID: 31027384
[TBL] [Abstract][Full Text] [Related]
14. Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia; Current Evidence, and Improving Outcomes Going Forward.
Leonard JT; Hayes-Lattin B
Curr Hematol Malig Rep; 2018 Aug; 13(4):329-340. PubMed ID: 30008035
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT.
Roth-Guepin G; Canaani J; Ruggeri A; Labopin M; Finke J; Cornelissen JJ; Delage J; Stuhler G; Rovira M; Potter M; Stadler M; Veelken H; Cahn JY; Collin M; Beguin Y; Giebel S; Nagler A; Mohty M
Oncotarget; 2017 Dec; 8(68):112972-112979. PubMed ID: 29348881
[TBL] [Abstract][Full Text] [Related]
16. Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression.
Kim DY; Park HS; Choi EJ; Lee JH; Lee JH; Jeon M; Kang YA; Lee YS; Seol M; Cho YU; Jang S; Chi HS; Lee KH; Park CJ
Blood Res; 2015 Dec; 50(4):227-34. PubMed ID: 26770950
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: potential benefit of medium-dose etoposide conditioning.
Imamura M; Shigematsu A
Exp Hematol Oncol; 2015; 4():20. PubMed ID: 26322249
[TBL] [Abstract][Full Text] [Related]
18. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
Pingali SR; Champlin RE
Bone Marrow Transplant; 2015 Sep; 50(9):1157-67. PubMed ID: 25985053
[TBL] [Abstract][Full Text] [Related]
19. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.
Kim M; Park J; Kim DW; Kim YJ; Jeon YW; Yoon JH; Shin SH; Yahng SA; Lee SE; Cho BS; Eom KS; Kim HJ; Min CK; Cho SG; Kim Y; Lee JW; Han K; Min WS; Lee S
Bone Marrow Transplant; 2015 Mar; 50(3):354-62. PubMed ID: 25501350
[TBL] [Abstract][Full Text] [Related]
20. Role of allogeneic hematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukemia.
Lussana F; Rambaldi A
Mediterr J Hematol Infect Dis; 2014; 6(1):e2014065. PubMed ID: 25408851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
